Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 15, 2008
Event: Entry into a Material Definitive Agreement regarding the distribution of FluLaval influenza vaccine.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a contractual amendment.
Material Changes
On October 15, 2008, Henry Schein, Inc. amended its Distribution Agreement with ID Biomedical Corporation for FluLaval influenza vaccine (originally dated December 2, 2004). The material changes include:
- Term Reduction: The agreement term is shortened by two years, now concluding at the end of the 2012/2013 flu season.
- Purchase Commitment Reduction: Henry Schein's maximum annual purchase commitment is reduced to 11.5 million doses.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of general risks and contingencies beyond the specific terms of the amended distribution agreement.
Investor Verification Checklist
- Verify the impact of the reduced purchase commitment (11.5 million doses) on future revenue projections for the vaccine segment.
- Confirm the financial implications of shortening the agreement term to the 2012/2013 flu season.
- Review the original 2004 Distribution Agreement to compare the previous purchase commitment levels and term length.